EP Wealth Advisors LLC acquired a new position in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 124,451 shares of the company's stock, valued at approximately $2,669,000. EP Wealth Advisors LLC owned approximately 0.08% of Adaptive Biotechnologies as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd purchased a new position in Adaptive Biotechnologies during the 4th quarter valued at about $28,000. Allworth Financial LP bought a new stake in shares of Adaptive Biotechnologies during the second quarter valued at about $35,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company's stock worth $38,000 after buying an additional 1,565 shares in the last quarter. KBC Group NV purchased a new stake in shares of Adaptive Biotechnologies in the first quarter worth about $45,000. Finally, Assetmark Inc. boosted its position in shares of Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company's stock valued at $49,000 after acquiring an additional 2,708 shares during the period. Hedge funds and other institutional investors own 99.17% of the company's stock.
Insider Transactions at Adaptive Biotechnologies
In related news, Director Peter M. Neupert sold 124,690 shares of the company's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $25.15, for a total value of $3,135,953.50. Following the completion of the transaction, the director directly owned 130,625 shares in the company, valued at approximately $3,285,218.75. The trade was a 48.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Sharon Benzeno sold 154,768 shares of the company's stock in a transaction on Monday, June 29th. The stock was sold at an average price of $21.14, for a total transaction of $3,271,795.52. Following the completion of the transaction, the insider owned 221,278 shares of the company's stock, valued at $4,677,816.92. This trade represents a 41.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 2,062,325 shares of company stock worth $46,659,069. Company insiders own 5.70% of the company's stock.
Adaptive Biotechnologies Stock Performance
Shares of ADPT opened at $25.99 on Friday. Adaptive Biotechnologies Corporation has a 12-month low of $12.00 and a 12-month high of $26.16. The company has a current ratio of 4.79, a quick ratio of 4.68 and a debt-to-equity ratio of 2.22. The company has a market cap of $4.15 billion, a PE ratio of -63.39 and a beta of 2.08. The stock has a 50-day moving average price of $22.06 and a 200-day moving average price of $17.35.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.12). The company had revenue of $71.55 million during the quarter, compared to the consensus estimate of $65.44 million. Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The firm's revenue for the quarter was up 21.5% on a year-over-year basis. During the same quarter last year, the company posted ($0.17) earnings per share. As a group, equities analysts forecast that Adaptive Biotechnologies Corporation will post -0.4 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities analysts recently commented on the stock. JPMorgan Chase & Co. reduced their price objective on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an "overweight" rating for the company in a research note on Wednesday, May 6th. Morgan Stanley increased their target price on shares of Adaptive Biotechnologies from $20.00 to $22.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 30th. Guggenheim raised their price target on shares of Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a "buy" rating in a report on Thursday, July 30th. TD Cowen boosted their price target on shares of Adaptive Biotechnologies from $25.00 to $28.00 and gave the company a "buy" rating in a research report on Thursday, July 30th. Finally, BTIG Research upped their price target on shares of Adaptive Biotechnologies from $24.00 to $25.00 and gave the stock a "buy" rating in a report on Thursday, July 30th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Adaptive Biotechnologies has an average rating of "Moderate Buy" and a consensus price target of $24.42.
Read Our Latest Analysis on ADPT
Adaptive Biotechnologies Profile
(
Free Report)
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
See Also
Want to see what other hedge funds are holding ADPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Adaptive Biotechnologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptive Biotechnologies wasn't on the list.
While Adaptive Biotechnologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
